The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
ApexOnco Front Page
Recent articles
The depressed company could use Mylotarg as a stepping stone in AML.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Claudin18.2 is out, but the US big pharma opts in to a new project.
The company sticks with EZH2, despite others adding EZH1 inhibition.
